A third dose of Pfizer Inc and BioNTech's Covid vaccine produced significant protection against the Omicron variant in healthy children aged between 5 and 11 years in a trial, the companies said on Thursday.

Blood serum analysis of a few pediatric participants who received a booster dose in the study showed a 36-fold increase in Omicron neutralising antibodies, the drugmakers said.